Ad
related to: diltiazem er brand name
Search results
Results From The WOW.Com Content Network
Diltiazem, sold under the brand name Cardizem among others, is a nondihydropyridine calcium channel blocker medication used to treat high blood pressure, angina, and certain heart arrhythmias. [9] It may also be used in hyperthyroidism if beta blockers cannot be used. [9] It is taken by mouth or given by injection into a vein. [9]
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification.
Name Image Brand name Citations Amlodipine: Norvasc, Istin, Normodipine, Tenox, Cordi Cor [4]Aranidipine: Sapresta (サプレスタ) [5]Azelnidipine: CalBlock (カルブロック)
AOL latest headlines, entertainment, sports, articles for business, health and world news.
If the wikilink of that drug name redirects to another drug name (eg trade name to generic) then mention it on the list. If a trade name should redirect to a generic name of a drug page that hasn't been created yet, include the redirect mention in the list but don't create a page that redirects to a non-existant page.
In June 2006, Teva received from the FDA a 180-day exclusivity period to sell simvastatin (Zocor) in the U.S. as a generic drug in all strengths except 80 mg. Teva presently [when?] competes with the maker of brand-name Zocor, Merck & Co.; Ranbaxy Laboratories, which has 180-day exclusivity for the 80 mg strength; and Dr. Reddy's Laboratories ...
Verapamil, sold under various trade names, [1] is a calcium channel blocker medication used for the treatment of high blood pressure, angina (chest pain from not enough blood flow to the heart), and supraventricular tachycardia. [9] It may also be used for the prevention of migraines and cluster headaches.
Angiotensin II treated patients are at an increased risk of thromboembolic events.There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received angiotensin II compared to placebo treated patients in the ATHOS-3 study [13% (21/163 patients) vs. 5% (8/158 patients)]. [9]